The Role of Recombinant Human Growth Hormone Biosimilars in the Management of Growth Disorders
The Role of Recombinant Human Growth Hormone Biosimilars in the Management of Growth Disorders
Published: September 2009
Abstract
Since ancient times plant and animal tissues have been used as medicines. In the 20th century growth hormone as a purified extraction from human pituitaries was still used to treat growth disorders. Since the genetic engineering of host cells became possible, a new generation of medicines obtained using recombinant DNA (rDNA) technology has emerged. These medicines have been named ‘biopharmaceuticals’. The first biopharmaceutical growth hormones were patented in the 1980s, so already over two decades of clinical experience support the development of a new, off-patent growth hormone preparation obtained by rDNA technology. The European Medicines Agency (EMEA) has put in place a centralised procedure for the approval of new biopharmaceuticals. This procedure includes testing comparability with a reference product and demands post-approval pharmacovigilance. Omnitrope® was the first off-patent recombinant human growth hormone (rhGH) approved on the basis of the biosimilar pathway; it underwent a very demanding approval procedure in 2006 and is now used for several indications in Europe, the US, Canada, Japan, Australia and other countries where it has received marketing approval.
Keywords
Off-patent biopharmaceuticals, growth hormone, Omnitrope®, EMEA centralised procedure, biosimilars, recombinant DNA (rDNA) technology,biologics, recombinant human growth hormone (rhGH), somatropin
Disclosure: Tomasz E Romer receives consulting fees from Sandoz.
Received: 13 July 2009 Accepted: 5 August 2009
Correspondence: Tomasz E Romer, ul Gardenii 8, 04-649 Warsaw, Poland. E: tomasz@romer.pl
Biologics
Biological medicines have been used since ancient times and are plant-derived. Healing plants were grown next to the temples of the ancient Egyptians and herbs to which therapeutic properties are attributed are still cultivated today. Phytotherapy still plays a considerable role in healthcare, although the safety and efficacy of applied herbal medicine procedures have not been proved using modern methods from evidence-based medicine. Animal tissue extracts are still used as biological medicine. More than 100 years ago it was found that pituitary extracts affect growth. Maurice Raben first isolated pituitary human growth hormone (pit-hGH) from human pituitaries collected at autopsy (1951) and used it in GH deficient patients (1958). Soon afterwards, a period of therapeutic use of pituitary-derived hGH, which has lasted for more than 20 years, began.
In the late 1970s, after many years of scientific research into DNA technology, the techniques of cutting at specific sites and replicating and synthesising DNA molecules greatly improved, and inserting specific DNA into bacterial or mammalian cells became possible. The host cell replicates inserted DNA in a natural way and synthesises the protein coded by the DNA. From that time on, it was possible to obtain active components of complex high-molecular-weight molecules for medical purposes. Continuous development of analytical methods and biological assays improved biotechnology methods, and thus an increasing number of complex molecules could be produced. Industrial manufacturing started in the early 1980s by cultivating genetically modified micro-organisms or cells, which was followed by purification of an active ingredient. Soon several important new drugs were patented; drugs obtained using this technique were called ‘biopharmaceuticals’ (see Figure 1). Insulin and GH were the first human hormones to be produced this way.
Adrenal Gland Supplements, Amino Acids Pituitary Gland, Bone Growth Disorders, Growth Disorders , HGH Products, HGH Releasers, HGH Supplements, Hormone Deficiency, Hormones Adrenal Gland, Human Grown Hormone Somatropin, Human Growth Hormone, Human Growth Hormone Anti Aging, Human Growth Hormone Disorders, Human Growth Hormone Pituitary Gland, Intrauterine Growth Retardation, Pituitary Gland Aging, Pituitary Gland Endocrine, Pituitary Gland Secretion, Precocious Puberty, The Pituitary Gland, Turner Syndrome
- Miller WL, Baxter JD, Recombinant DNA – a new source of insulin, Diabetologia, 1980;18:431–6.
- Dean HJ, Friesen HG, Growth therapy in Canada: end of one ere and beginning of another, Can Med Assoc J, 1986;135:297–301.
- Takano K, Shizume K, Hizuka N, et al., Treatment of idiopathic pituitary dwarfism with methionyl human growth hormone, Endocrinol Jpn, 1983;30:523–7.
- Kaplan SL, Undrewood LE, August GP, et al., Clinical studies with recombinant-DNA-derived methionyl human growth hormone in growth hormone deficient children, Lancet, 1986;1:697–700.
- Girard F, Gourmelen M, Clinical experience with Somatonorm, Acta Paediatr Scand Suppl, 1986;325:29–32.
- Milner RD, Clinical experience of somatrem: UK preliminary report, Acta Paediatr Scand Suppl, 1986;325: 25–8.
- Bierich JR, Treatment of pituitary dwarfism with biosynthetic growth hormone, Acta Paediatr Scand Suppl, 1986;325:13–18.
- Ranke MB, Wilton P (eds), Growth Hormone Therapy in KIGS – 10 Years’ Experience, Heidelberg, Leipzig: Johann Ambrosius Barth Verlag, 1999.
- Romer T, Peter F, Saenger P, Starzyk J, Koehler B, Korman E, Walczak M, Efficacy and safety of a new ready-to-use recombinant human growth hormone solution, J Endocrinol Invest, 2007;30:578–89.
- Romer T, Saenger P, Peter F, et al., Seven years of safety and efficacy of the recombinant human Growth Hormone Omnitrope® in the treatment of Growth Hormone Deficient children: results of a phase III study, Hormone Res, 2009; in press.
- Coste J, Letrait M, Carel JC, et al., Long-term results of growth hormone treatment in France in children of short stature: population, register based study, BMJ, 1997;315:708–13.
- Cohen P, Bright GM, Rogol AD, et al., Effects of dose and gender on the growth and growth factor response to GH in GH-deficient children: implications for efficacy and safety, J Clin Endocrinol Metab, 2002;87:90–98.
- Vicens-Calvet E, Cuatrecasas-Membrado JM, Spanish multicentre trial of recombinant somatropin. Spanish Collaborative Group, Acta Paediatr Scand Suppl, 1988;347:180–83.
- De Muinck Keizer-Schrama S, Rikken B, Hokken-Koelega A, et al., Comparative effect of two doses of growth hormone for growth hormone deficiency. The Dutch Growth Hormone Working Group, Arch Dis Child, 1994;71: 12–18.
- Bercu BB, Murray FT, Frasier SD, et al., Long-term therapy with recombinant human growth hormone (Saizen) in children with idiopathic and organic growth hormone deficiency, Endocrine, 2001;15:43–9.
- Root AW, Kemp SF, Rundle AC, et al., Effect of long-term recombinant growth hormone therapy in children-the National Cooperative Growth Study, USA, 1985–1994, J Pediatr Endocrinol Metab, 1998;11:403–12.
- Reiter EO, Price DA, Wilton P, et al., Effect of growth hormone (GH) treatment on the near-final height of 1258 patients with idiopathic GH deficiency: analysis of a large international database, J Clinl Endocrinol Metab, 2006;91:2047–54.






